2 April 2019:
Professor Ewa Goldys, CNBP Deputy Director, UNSW Sydney, in partnership with Associate Professor Shane Grey from the Garvan Institute have received an international grant from JDRC for “Noninvasive assessment of islet cells”.
This project will develop a non-invasive method for real-time monitoring of encapsulated beta cells in vitro and in vivo. This will help assess the fate of implanted cells and define the conditions required to produce high quality insulin-producing cells for implantation and their precursors.
The results will lay the foundations for in vivo assessment of islet transplantation success.
14 January 2019:
A new paper by CNBP researchers and colleagues (including CNBP Associate Investigator Guozhen Liu, UNSW Sydney) reviews cutting-edge biosensing applications of CRISPR.
Journal: Trends in Biotechnology.
Publication title: CRISPR/Cas Systems towards Next-Generation Biosensing.
Authors: Yi Li, Shiyuan Li, Jin Wang and Guozhen Liu.
Abstract: Beyond its remarkable genome editing ability, the CRISPR/Cas9 effector has also been utilized in biosensing applications. The recent discovery of the collateral RNA cleavage activity of the Cas13a effector has sparked even greater interest in developing novel biosensing technologies for nucleic acid detection and promised significant advances in CRISPR diagnostics. Now, along with the discovery of Cas12 collateral cleavage activities on single stranded DNA (ssDNA), several CRISPR/Cas systems have been established for detecting various targets, including bacteria, viruses, cancer mutations, and
others. Based on key Cas effectors, we provide a detailed classification of CRISPR/Cas biosensing systems and propose their future utility. As the field continues to mature, CRISPR/Cas systems have the potential to become promising candidates for next-generation diagnostic biosensing platforms.